More Zelira Therapeutics Ltd. news
Zelira Therapeutics Ltd.ASX: ZLD

First Patient Dosed in Zelda Insomnia Trial

Sep 25, 2018 at 10:45 PM EDT · Issued by Zelira Therapeutics Ltd.

Filed with ASX · Sep 25, 2018 at 10:45 PM EDT

On 6ix: 6ix.com/news/first-patient-dosed-in-zelda-insomnia-trial

Zelira Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Zelira Therapeutics Ltd. on 6ix

In the deck

  • Zelda Therapeutics — Investor Presentation (September 2018)27 slidesSep 25, 2018

Earlier from Zelira Therapeutics

  • Zelda Forms New Partnership to Access German MarketSep 3, 2018
  • June 2018 Quarterly ReportJul 29, 2018
  • Commencement of New Managing DirectorJul 15, 2018
  • Appointment of Managing DirectorMay 21, 2018
  • March 2018 Quarterly ReportApr 29, 2018

Later from Zelira Therapeutics

  • US Autism Observational Study UnderwayOct 9, 2018
  • Zelda Focuses Clinical Trial ActivityOct 10, 2018
  • September 2018 Quarterly ReportOct 31, 2018
  • Opioid reduction clinical trial with St Vincents HospitalNov 25, 2018
  • ZLD to Invest in Development of Oral Spray FormulationsDec 5, 2018
All Zelira Therapeutics news releases↗

Follow Zelira Therapeutics into a list and get an email when it puts out news.

Follow Zelira Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer